Multivitamins and phospholipids complex protects the hepatic cells from androgenic-anabolic-steroids-induced toxicity

References

• Mottram DR, George AJ. Anabolic steroids. Baillieres Best Pract Res Clin Endocrinol Metab Mar 2000; 14(1)55–69
   PubMed Web of Science ®Google Scholar
• Kuhn CM. Anabolic steroids. Recent Prog Horm Res 2002; 57: 411–34
   PubMedGoogle Scholar
• Jamin C. The concept of selective action steroids. Gynecol Obstet Fertil 2000; 28(12)931–9
   PubMedGoogle Scholar
• Mooradian AD, Morely JE, Korenman SG. Biological actions of androgens. Endocrine Reviews 1987; 8: 1–28
   PubMed Web of Science ®Google Scholar
• Yesalis CE, Bahrke MS. Anabolic-androgenic steroids and related substances. Curr Sports Med Rep 2002; 1(4)246–52
   PubMedGoogle Scholar
• Kutscher EC, Lund BC, Perry PJ. Anabolic steroids: A review for the clinician. Sports Med 2002; 32(5)285–96
   PubMed Web of Science ®Google Scholar
• Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 2001; 23(9)1355–90
   PubMed Web of Science ®Google Scholar
• Kicman AT, Gower DB. Anabolic steroids in sport: biochemical, clinical and analytical perspectives. Ann Clin Biochem 2003; 40(Pt. 4)321–56
   PubMedGoogle Scholar
• Pavlatos AM, Fultz O, Monberg MJ, et al. Review of oxymetholone: A 17alpha-alkylated anabolic-androgenic steroid. Clin Ther 2001; 23(6)789–801
   PubMed Web of Science ®Google Scholar
• Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med 2004; 32(2)534–42
   PubMed Web of Science ®Google Scholar
• O'sullivan AJ, Kennedy MC, Casey JH, et al. Anabolic-androgenic steroids: Medical assessment of present, past and potential users. Med J Aust 2000; 173(6)323–7
   PubMed Web of Science ®Google Scholar
• Griggs RC, Kingston W, Jozefowicz RF, Herr BF, Forbes G, Halliday D. Effects of testosterone on muscle mass and protein synthesis. J Appl Physiol 1989; 66: 498–503
   PubMed Web of Science ®Google Scholar
• Tamaki T, Uchiyama S, Uchiyama Y, et al. Anabolic steroids increase exercise tolerance. Am J Physiol Endocrinol Metab 2001; 280(6)E973–81
   Google Scholar
• Rogol AD. Sex steroid and growth hormone supplementation to enhance performance in adolescent athletes. Curr Opin Pediatr 2000; 12(4)382–7
   PubMed Web of Science ®Google Scholar
• Inigo MA, Arrimadas E, Arroyo D. 43 cycles of anabolic steroid treatment studied in athletes: The uses and secondary effects. Rev Clin Esp 2000; 200(3)133–8
   PubMedGoogle Scholar
• Perry PJ, Andersen KH, Yates WR. Illicit anabolic steroid use in athletes: A case series analysis. Am J Sports Med 1990; 18: 422–428
   PubMed Web of Science ®Google Scholar
• Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med 2004; 34(8)513–54
   PubMed Web of Science ®Google Scholar
• Feller AA, Mylonakis E, Rich JD. Medical complications of anabolic steroids. Med Health R I 2002; 85(11)338–40
   PubMedGoogle Scholar
• Stimac D, Milic S, Dintinjana RD, et al. Androgenic/Anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 2002; 35(4)350–2
   PubMed Web of Science ®Google Scholar
• Segal S, Cooper J, Bolognia J. Treatment of lipodermatosclerosis with oxandrolone in a patient with stanozolol-induced hepatotoxicity. J Am Acad Dermatol 2000; 43(3)558–9
   PubMed Web of Science ®Google Scholar
• Teschke R. Drug-induced liver diseases. Z Gastroenterol 2002; 40(5)305–26
   PubMed Web of Science ®Google Scholar
• Nakao A, Sakagami K, Nakata Y, et al. Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis. J Gastroenterol 2000; 35(7)557–62
   PubMed Web of Science ®Google Scholar
• Bolding G, Sherr L, Elford J. Use of anabolic steroids and associated health risks among gay men attending London gyms. Addiction 2002; 97(2)195–203
   PubMed Web of Science ®Google Scholar
• Pertusi R, Dickerman RD, McConathy WJ. Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: Hepatitis or rhabdomyolysis?. J Am Osteopath Assoc 2001; 101(7)391–4
   PubMedGoogle Scholar
• Thomas S, Wolf SE, Murphy KD, et al. The long-term effect of oxandrolone on hepatic acute phase proteins in severely burned children. J Trauma 2004; 56(1)37–44
   PubMed Web of Science ®Google Scholar
• Urhausen A, Torsten A, Wilfried K. Reversibility of the effects on blood cells, lipids, liver function and hormones in former anabolic-androgenic steroid abusers. J Steroid Biochem Mol Biol 2003; 84(2–3)369–75
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Weinrieb RM, Calarco JS, et al. An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: Seven case studies. Ann Clin Psychiatry 2003; 15(2)121–30
   PubMedGoogle Scholar
• Green GA, Uryasz FD, Petr TA, et al. NCAA study of substance use and abuse habits of college student-athletes. Clin J Sport Med 2001; 11(1)51–6
   PubMed Web of Science ®Google Scholar
• Laure P. Doping: Epidemiological studies. Presse Med 2000; 29(24)1365–72
   PubMedGoogle Scholar
• Millman RB, Ross EJ. Steroid and nutritional supplement use in professional athletes. Am J Addict 2003; 12(Suppl 2)S48–54
   Google Scholar
• Ishak KG, Zimmerman HJ. Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis 1987; 7: 230–236
   PubMed Web of Science ®Google Scholar
• Hickson RC, Ball KL, Falduto MT. Adverse effects of anabolic steroids. Med Toxicol Adverse Drug Exp 1989; 4: 254–271
   PubMedGoogle Scholar
• de Silva HA, Saparamadu PA, Thabrew MI, et al. Liv.52 in alcoholic liver disease: A prospective, controlled trial. J Ethnopharmacol 2003; 84(1)47–50
   PubMed Web of Science ®Google Scholar
• Horejsova M, Urban J. The effect of polyene phosphatidylcholine (Essentiale forte) in the treatment of liver steatosis and ultrasound findings, a preliminary study. Cas Lek Cesk 1994; 133(12)366–9
   PubMedGoogle Scholar
• Lata J, Dastych M, Senkyrik M, et al. Protective effect of essential phospholipids on liver injury due to total parenteral nutrition. Vnitr Lek 2001; 47(9)599–603
   PubMedGoogle Scholar
• Prokopenko LG, Konoplia NA, Uteshev BS. Effect of essentiale and riboxin on immunosuppressive properties of thrombocytes and erythrocytes during liver intoxication. Eksp Klin Farmakol 2001; 64(4)37–41
   PubMedGoogle Scholar
• Shpagina LA, Bobrov SV. Administration of essential phospholipids in persons exposed to chemical industrial pollutants. Ter Arkh 2004; 76(2)63–6
   PubMed Web of Science ®Google Scholar
• Inigo MA, Arrimadas E, Arroyo D. 43 cycles of anabolic steroid treatment studied in athletes: the uses and secondary effects. Rev Clin Esp 2000; 200(3)133–8
   PubMedGoogle Scholar
• Berning JM, Adams KJ, Stamford BA. Anabolic steroid usage in athletics: Facts, fiction, and public relations. J Strength Cond Res 2004; 18(4)908–17
   PubMed Web of Science ®Google Scholar
• Gomez JE. Performance-enhancing substances in adolescent athletes. Tex Med 2002; 98(2)41–6
   PubMedGoogle Scholar
• Irving LM, Wall M, Neumark-Sztainer D, et al. Steroid use among adolescents: Findings from Project EAT. J Adolesc Health 2002; 30(4)243–52
   PubMed Web of Science ®Google Scholar
• Wichstrom L, Pedersen W. Use of anabolic-androgenic steroids in adolescence: Winning, looking good or being bad?. J Stud Alcohol 2001; 62(1)5–13
   PubMed Web of Science ®Google Scholar
• Hartgens F, van Straaten H, Fideldij S, et al. Misuse of androgenic-anabolic steroids and human deltoid muscle fibers: Differences between polydrug regimens and single drug administration. Eur J Appl Physiol 2002; 86(3)233–9
   PubMed Web of Science ®Google Scholar
• Pagonis TA, Angelopoulos NV, Koukoulis GN, Hadjichristodoulou CS. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. European Psychiatry, in press
   Web of Science ®Google Scholar
• Paul GL. Dietary protein requirements of physically active individuals. Sports Med 1989; 8(3)154–176
   PubMed Web of Science ®Google Scholar
• Jarvis M, McNaughton L, Seddon A, et al. The acute 1-week effects of the Zone diet on body composition, blood lipid levels, and performance in recreational endurance athletes. J Strength Cond Res 2002; 16(1)50–7
   PubMed Web of Science ®Google Scholar
• Ziegler P, Nelson JA, Barratt-Fornell A, et al. Energy and macronutrient intakes of elite figure skaters. J Am Diet Assoc 2001; 101(3)319–25
   PubMed Web of Science ®Google Scholar
• Peterson MD, Rhea MR, Alvar BA. Maximizing strength development in athletes: A meta-analysis to determine the dose-response relationship. J Strength Cond Res 2004; 18(2)377–82
   PubMed Web of Science ®Google Scholar
• Marcos J, Pascual JA, de la Torre X, et al. Fast screening of anabolic steroids and other banned doping substances in human urine by gas chromatography/tandem mass spectrometry. J Mass Spectrom 2002; 37(10)1059–73
   PubMed Web of Science ®Google Scholar
• Trout GJ, Kazlauskas R. Sports drug testing-an analyst's perspective. Chem Soc Rev 2004; 33(1)1–13
   PubMed Web of Science ®Google Scholar
• Dickerman RD, Pertusi RM, Zachariah NY, Dufour DR, McConathy WJ. Anabolic steroid-induced hepatotoxicity: Is it overstated?. Clin J Sport Med 1999; 9(1)34–9
   PubMed Web of Science ®Google Scholar
• Boada LD, et al. Evaluation of acute and chronic hepatotoxic effects exerted by anabolic-androgenic steroid stanozolol in adult male rats. Archives of Toxicology 1999; 73: 465–72
   PubMed Web of Science ®Google Scholar
• Horejsova M, Urban J. The effect of polyene phosphatidylcholine (Essentiale forte) in the treatment of liver steatosis and ultrasound findings, a preliminary study. Cas Lek Cesk 1994; 133(12)366–9
   PubMedGoogle Scholar
• Mitra SK. Herbal products for liver diseases. Hepatology 2000; 31(2)546–7
   PubMed Web of Science ®Google Scholar
• Dhiman RK. Herbal hepatoprotective agents: Marketing gimmick or potential therapies?. Trop Gastroenterol 2003; 24(3)160–2
   PubMedGoogle Scholar
• Radovanovic D, Jovanovic D, Mihailovic D, et al. Hepatoprotective effects of silymarin in androgenic-anabolic steroid-induced liver damage. Med Pregl (Yugoslavia) 2003; 56(suppl. 1)79–83
   PubMedGoogle Scholar
• Berger J, Kowdley KV. Is silymarin hepatoprotective in alcoholic liver disease?. J Clin Gastroenterol 2003; 37(4)278–9
   PubMed Web of Science ®Google Scholar
• Soto C, Recoba R, Barron H, et al. Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas. Comp Biochem Physiol C Toxicol Pharmacol 2003; 136(3)205–12
   PubMed Web of Science ®Google Scholar
• Lieber CS, Leo MA, Cao Q, et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003; 37(4)336–9
   PubMed Web of Science ®Google Scholar
• de Silva HA, Saparamadu PA, Thabrew MI, et al. Liv.52 in alcoholic liver disease: A prospective, controlled trial. J Ethnopharmacol 2003; 84(1)47–50
   PubMed Web of Science ®Google Scholar
• Atoba MA, Ayoola EA, Ogunseyinde O. Effects of essential phospholipid choline on the course of acute hepatitis-B infection. Trop Gastroenterol 1985; 6: 96–9
   PubMedGoogle Scholar
• Canty DJ, Zeisel SH. Lecithin and choline in human health and disease. Nutr Rev 1994; 52: 327–339
   PubMed Web of Science ®Google Scholar
• Lecithin. Technological, Biological and Therapeutic Aspects, I Hanin, GB Ansell. Plenum Press, New York and London 1987; 38–99; 104–125
   Google Scholar
• Jenkins PJ, Portmann BP, Eddleston AL, Williams R. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: Results of prospective double-blind controlled trial. Liver 1982; 2: 7–81
   Google Scholar
• Kosina F, Budka K, Kolouch Z, et al. Essential cholinephospholipids in the treatment of virus hepatitis. Cas Lek Cesk 1981; 120: 957–960
   PubMedGoogle Scholar
• Lieber CS, Leo MA, Cao Q, et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 2003; 37(4)336–9
   PubMed Web of Science ®Google Scholar
• Visco G. Polyunsaturated phosphatidylcholine in association with vitamin B complex in the treatment of acute viral hepatitis B results of a randomized double-blind clinical study. Clin Ter 1985; 114: 183–188
   PubMedGoogle Scholar
• Aleynik SI, Leo MA, Ma X, Aleynik MK, Lieber CS. Polyenylphosphatidylcholine protects against alcoholic cirrhosis in the baboon and carbon tetrachloride-induced cirrhosis in rats. J Hepatol 1997; 27(3)554–61
   PubMed Web of Science ®Google Scholar
• Canty DJ, Zeisel SH. Lecithin and choline in human health and disease. Nutr Rev 1994; 52: 327–339
   PubMed Web of Science ®Google Scholar
• Navder KP, Baraona E, Lieber CS. Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. J Nutr 1997; 127(9)1800–6
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Bai L, Namba M. Extending effects of phospholipids, cholesterol, and ethanolamines on survival of adult rat hepatocytes in serum-free primary culture. Res Exp Med (Berl) 1991; 191(2)77–83
   PubMedGoogle Scholar